About
LicensingBioLink WeeklyJob BoardNewsContact Us

BioLink Weekly

Intelligence for US-China Biopharma Dealmakers. Published weekly by BioRich International, Princeton NJ.

Subscribe Free7 issues published
Latest Issue
Issue 7May 24, 2026

PROTACs Enter Commercial Licensing; Gilead Closes $5B Tubulis; Lilly Makes Its 7th Acquisition of 2026

Rigel takes global rights to Veppanu — the first FDA-approved PROTAC — in an $85M near-term, $445M total deal that anchors the protein-degrader valuation template. Gilead's Tubulis acquisition closes at $5B (its first dedicated ADC buy of 2026), and Eli Lilly picks up Engage Biologics' non-viral DNA delivery platform — its seventh acquisition of the year.

Read Full Issue

In This Issue

  • M&A & Licensing
  • PROTAC Debut
  • BD&L Mandates
  • CRISPR & HBV
Previous Issues
6May 16, 2026

BMS–Hengrui $15.2B Anchors a Three-Week Deal Wave; Lilly and Novo Reshape the Global Top 10

  • M&A & Licensing
  • Top 10 Reshuffle
  • Open BD&L Roles
Read issue
5April 26, 2026

AI Moves From Pilot to Production as Q1 Deal Wave Continues

  • M&A & Licensing
  • AI in Biopharma
  • BD&L Mandates
Read issue
4April 19, 2026

ADCs and Radiopharma Lead the Mid-April Deal Wave; 22,000+ MNC Layoffs Reshape the Industry

  • M&A & Licensing
  • MNC Layoff Report
  • BD&L Mandates
Read issue
3April 12, 2026

CRO/CDMO Landscape Shifts as US Biotechs Reassess China Manufacturing Partnerships

  • Featured Deal
  • Market Moves
  • Regulatory Watch
Read issue
2April 6, 2026

In-Licensing Appetite Among US Mid-Caps Reaches Post-Pandemic Peak

  • Featured Deal
  • Market Moves
  • Regulatory Watch
Read issue
1March 31, 2026

Launching BioLink Weekly: Your Intelligence Source for US-China Biopharma Deals

  • Launch Edition
  • Market Overview
  • Regulatory Watch
Read issue
Subscribe

Stay Ahead of the Market

BioLink Weekly delivers curated US-China biopharma deal intelligence directly to your inbox. Free, every week.